NCT01727986View on ClinicalTrials.gov

An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks

Trial Locations (4)

20551030

Rio de Janeiro

21941-912

Rio de Janeiro

90035-003

Porto Alegre

05403-000

São Paulo

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01727986 - An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study | Biotech Hunter | Biotech Hunter